These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24407918)

  • 41. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.
    Heath RJ; Rock CO
    J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
    Sampson PB; Picard C; Handerson S; McGrath TE; Domagala M; Leeson A; Romanov V; Awrey DE; Thambipillai D; Bardouniotis E; Kaplan N; Berman JM; Pauls HW
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5355-8. PubMed ID: 19682901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
    Kim YG; Seo JH; Kwak JH; Shin KJ
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
    Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
    J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
    Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
    ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanism of triclosan inhibition of bacterial fatty acid synthesis.
    Heath RJ; Rubin JR; Holland DR; Zhang E; Snow ME; Rock CO
    J Biol Chem; 1999 Apr; 274(16):11110-4. PubMed ID: 10196195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical and structural characterization of the trans-enoyl-CoA reductase from Treponema denticola.
    Bond-Watts BB; Weeks AM; Chang MC
    Biochemistry; 2012 Aug; 51(34):6827-37. PubMed ID: 22906002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
    Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
    J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
    Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
    Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.
    Neckles C; Pschibul A; Lai CT; Hirschbeck M; Kuper J; Davoodi S; Zou J; Liu N; Pan P; Shah S; Daryaee F; Bommineni GR; Lai C; Simmerling C; Kisker C; Tonge PJ
    Biochemistry; 2016 May; 55(21):2992-3006. PubMed ID: 27136302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.
    Kim KH; Park JK; Ha BH; Moon JH; Kim EE
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Mar; 63(Pt 3):246-8. PubMed ID: 17329825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition.
    Roujeinikova A; Sedelnikova S; de Boer GJ; Stuitje AR; Slabas AR; Rafferty JB; Rice DW
    J Biol Chem; 1999 Oct; 274(43):30811-7. PubMed ID: 10521472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.
    Tipparaju SK; Mulhearn DC; Klein GM; Chen Y; Tapadar S; Bishop MH; Yang S; Chen J; Ghassemi M; Santarsiero BD; Cook JL; Johlfs M; Mesecar AD; Johnson ME; Kozikowski AP
    ChemMedChem; 2008 Aug; 3(8):1250-68. PubMed ID: 18663709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase.
    Zhu L; Lin J; Ma J; Cronan JE; Wang H
    Antimicrob Agents Chemother; 2010 Feb; 54(2):689-98. PubMed ID: 19933806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
    Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of the crystal structure and active residues of FabV, the enoyl-ACP reductase from Xanthomonas oryzae.
    Li H; Zhang X; Bi L; He J; Jiang T
    PLoS One; 2011; 6(10):e26743. PubMed ID: 22039545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
    Tipparaju SK; Joyasawal S; Forrester S; Mulhearn DC; Pegan S; Johnson ME; Mesecar AD; Kozikowski AP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3565-9. PubMed ID: 18499454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The kalimantacin/batumin biosynthesis operon encodes a self-resistance isoform of the FabI bacterial target.
    Mattheus W; Masschelein J; Gao LJ; Herdewijn P; Landuyt B; Volckaert G; Lavigne R
    Chem Biol; 2010 Oct; 17(10):1067-71. PubMed ID: 21035728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Celastrol inhibits Plasmodium falciparum enoyl-acyl carrier protein reductase.
    Tallorin LC; Durrant JD; Nguyen QG; McCammon JA; Burkart MD
    Bioorg Med Chem; 2014 Nov; 22(21):6053-6061. PubMed ID: 25284249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
    Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
    J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.